Abiopharma

🔍 BURNETT JOSEPH (Executive)

Company: ClearPoint Neuro, Inc. (CLPT)

Report Date: 2026-03-12

Detailed Transactions and Holdings:

• Acquired 84,829 shares of Common Stock (Direct)
  Date: 2026-03-12 | Code: M | equity_swap_involved: false | shares_owned_after: 139,061.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 43,161 shares of Common Stock at $11.53 per share (Direct)
  Date: 2026-03-12 | Code: F | equity_swap_involved: false | shares_owned_after: 95,900.00 | transaction_form_type: 4 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-12 | Code: H | nature_of_ownership: See footnote | shares_owned_after: 193,231.00 | Footnotes: F3
• Sold 84,829 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-12 | Code: M | equity_swap_involved: false | shares_owned_after: 84,828.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1

Footnotes:

• F1: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.
• F2: Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock.
• F3: These shares are owned directly by the Joseph M. Burnett Trust dated 10/20/2022 and indirectly by Joseph M. Burnett as trustee of the trust.